Spark’s gene therapy data answer some burning questions — and raise a few more

An investigational hemophilia A treatment from Spark Therapeutics reduced bleeds by nearly 100 percent in a small clinical trial, improving upon earlier data that left investors unsatisfied. But it still remains to be seen whether Spark’s gene therapy can beat out a rival effort underway at BioMarin.